Analog communication is having a moment, ironically thanks to digital platforms where people share product info and connect ...

For the past decade, the “Ghost of Reem Island,” as she was referred to in the press, has haunted me.

Brands are increasingly choosing recycled papers, bamboo card stock, and agricultural waste byproducts as ... with letterforms pushing boundaries regarding size, weight, and positioning on the card.

By Gina Kolata and Rebecca Robbins A daily pill may be as effective in lowering blood sugar and aiding weight loss in people with Type 2 diabetes as the popular injectable drugs Mounjaro and ...

Shares of obesity drug developers were volatile this week amid good news for Eli Lilly's (LLY) drug candidate orforglipron, bad news for Pfizer's (PFE) danuglipron and uncertainty about whether ...

Ore Huiying / Bloomberg / Getty Images Shares of Eli Lilly jumped 16% Thursday morning after the pharmaceutical company released Phase 3 trial results for its oral weight-loss drug that ...

The experimental pill resulted in weight loss of nearly 8% at the highest dose, and lowered blood sugar in patients with type 2 diabetes. Today's pop helped Eli Lilly stock fully recover from its ...

Shares in pharmaceuticals firm Eli Lilly (LLY) ballooned higher today after revealing its new needle-free weight loss drug had performed strongly in trials. Discover outperforming stocks and ...

Pfizer (NYSE:PFE) shares traded lower in the premarket after the pharma giant said it would no longer develop its oral weight loss therapy, danuglipron, following a liver injury found in a ...

(AP Photo/Darron Cummings, File)(Darron Cummings / AP) Eli Lilly & Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step ...

Eli Lilly (LLY) stock surges after releasing promising test results from the company's GLP-1 pill, which would serve as an alternative to injectable weight-loss drugs. Novo Nordisk (NVO ...

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral weight-loss drug news and BMO cut its rating for the Danish drug developer's ...